These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20403046

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma.
    Bao ST, Gui SQ, Lin MS.
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):580-3. PubMed ID: 17085346
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.
    Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y.
    J Exp Clin Cancer Res; 2005 Sep; 24(3):415-21. PubMed ID: 16270528
    [Abstract] [Full Text] [Related]

  • 10. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma.
    Takashima H, Nakajima T, Moriguchi M, Sekoguchi S, Nishikawa T, Watanabe T, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, Okanoue T.
    Liver Int; 2005 Feb; 25(1):77-84. PubMed ID: 15698402
    [Abstract] [Full Text] [Related]

  • 11. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
    Sakai M, Hibi K, Kanazumi N, Nomoto S, Inoue S, Takeda S, Nakao A.
    Hepatogastroenterology; 2005 Feb; 52(66):1854-7. PubMed ID: 16334792
    [Abstract] [Full Text] [Related]

  • 12. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma.
    Ko E, Kim Y, Kim SJ, Joh JW, Song S, Park CK, Park J, Kim DH.
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2260-7. PubMed ID: 18723830
    [Abstract] [Full Text] [Related]

  • 13. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.
    Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4171-7. PubMed ID: 16857788
    [Abstract] [Full Text] [Related]

  • 14. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas.
    Zhang Y, Huang D, Yu G.
    Acta Otolaryngol; 2005 Dec 15; 125(12):1345-50. PubMed ID: 16303685
    [Abstract] [Full Text] [Related]

  • 15. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.
    Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW, Lui WY.
    Oncol Rep; 2006 Feb 15; 15(2):507-11. PubMed ID: 16391877
    [Abstract] [Full Text] [Related]

  • 16. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
    Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ.
    Liver Int; 2005 Apr 15; 25(2):266-72. PubMed ID: 15780049
    [Abstract] [Full Text] [Related]

  • 17. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
    Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW.
    Cancer; 2006 Aug 01; 107(3):579-90. PubMed ID: 16795071
    [Abstract] [Full Text] [Related]

  • 18. Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation.
    Zhang W, Zhou L, Ding SM, Xie HY, Xu X, Wu J, Chen QX, Zhang F, Wei BJ, Eldin AT, Zheng SS.
    Oncol Rep; 2011 Apr 01; 25(4):1053-62. PubMed ID: 21271221
    [Abstract] [Full Text] [Related]

  • 19. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.
    Mol Cancer; 2008 Nov 06; 7():83. PubMed ID: 18990230
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.